Free Trial
→ The investigation Porter spent tens of thousands to document (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lipocine Inc. stock logo
LPCN
Lipocine
$1.72
-10.9%		$2.16
$1.72
▼
$12.37
$14.18M0.45.44 million shs1.03 million shs
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
$1.10
-2.7%		$1.37
$0.95
▼
$6.17
$4.58M2.3249,877 shs67,437 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$5.30
+25.0%		$3.89
$1.11
▼
$17.50
$17.87M0.382,785 shs3,905 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lipocine Inc. stock logo
LPCN
Lipocine
-10.88%-16.10%-23.56%-28.63%-45.57%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-2.65%+0.92%-19.71%-17.91%-81.39%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
+25.00%+32.17%+70.29%+9.75%-55.83%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lipocine Inc. stock logo
LPCN
Lipocine
$1.72
-10.9%		$2.16
$1.72
▼
$12.37
$14.18M0.45.44 million shs1.03 million shs
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
$1.10
-2.7%		$1.37
$0.95
▼
$6.17
$4.58M2.3249,877 shs67,437 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$5.30
+25.0%		$3.89
$1.11
▼
$17.50
$17.87M0.382,785 shs3,905 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lipocine Inc. stock logo
LPCN
Lipocine
-10.88%-16.10%-23.56%-28.63%-45.57%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-2.65%+0.92%-19.71%-17.91%-81.39%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
+25.00%+32.17%+70.29%+9.75%-55.83%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lipocine Inc. stock logo
LPCN
Lipocine
2.00
Hold$4.00132.56% Upside
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
1.00
SellN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NCNA, LPCN, and ZIVO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/9/2026
Lipocine Inc. stock logo
LPCN
Lipocine
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/24/2026
Lipocine Inc. stock logo
LPCN
Lipocine
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
9/22/2026
Lipocine Inc. stock logo
LPCN
Lipocine
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/21/2026
Lipocine Inc. stock logo
LPCN
Lipocine
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$4.00
9/3/2026
Lipocine Inc. stock logo
LPCN
Lipocine
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/19/2026
Lipocine Inc. stock logo
LPCN
Lipocine
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lipocine Inc. stock logo
LPCN
Lipocine
$1.57M9.03N/AN/A$2.61 per share0.66
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/AN/AN/AN/A$7.71 per shareN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$15.85K1,409.43N/AN/A($0.81) per share-6.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lipocine Inc. stock logo
LPCN
Lipocine
-$9.63M-$1.79N/AN/AN/A-755.39%-64.75%-57.62%11/5/2026 (Estimated)
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-$38.71M-$3.81N/AN/AN/AN/A-41.90%-33.69%11/12/2026 (Estimated)
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
-$7.78M-$1.40N/AN/AN/AN/AN/A-2,240.92%12/2/2026 (Estimated)

Latest NCNA, LPCN, and ZIVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Lipocine Inc. stock logo
LPCN
Lipocine
-$0.39N/AN/AN/A$0.16 millionN/A
8/13/2026Q2 2026
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-$2.6514-$0.99+$1.6614N/AN/AN/A
8/4/2026Q2 2026
Lipocine Inc. stock logo
LPCN
Lipocine
-$0.40-$0.32+$0.08-$0.32$0.21 million$0.19 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Lipocine Inc. stock logo
LPCN
Lipocine
N/AN/AN/AN/AN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/AN/AN/AN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lipocine Inc. stock logo
LPCN
Lipocine
N/A
11.48
11.48
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/A
4.73
4.73
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/A
0.17
0.17

Institutional Ownership

CompanyInstitutional Ownership
Lipocine Inc. stock logo
LPCN
Lipocine
9.11%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
44.00%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
12.83%

Insider Ownership

CompanyInsider Ownership
Lipocine Inc. stock logo
LPCN
Lipocine
4.69%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
31.20%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
48.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lipocine Inc. stock logo
LPCN
Lipocine
148.24 million7.86 millionNo Data
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
114.16 million2.86 millionNot Optionable
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
104.22 million2.91 millionNot Optionable

Recent News About These Companies

Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace
May 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260512411739/en/zivo-bioscience-inc.-announces-transition-to-otcid-marketplace/
Zivo Bioscience Inc. Wt
April 11, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/zivow
ZIVO Bioscience Provides Special Letter to Shareholders
March 27, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260327190358/en/ZIVO-Bioscience-Provides-Special-Letter-to-Shareholders/
Maxim Group Reaffirms Their Hold Rating on Zivo Bioscience (ZIVO)
December 15, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ZIVO/pressreleases/36474537/maxim-group-reaffirms-their-hold-rating-on-zivo-bioscience-zivo/
ZIVO Bioscience releases letter to shareholders
September 14, 2025  |  wattagnet.comW
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
September 10, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250910182550/en/zivo-bioscience-ceo-letter-to-shareholders-highlights-progress-with-human-nutrition-and-animal-therapeutic-businesses/
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry
June 20, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250620564330/en/zivo-bioscience-and-leading-global-animal-health-company-to-advance-zivo%e2%80%99s-immune-enhancing-compounds-in-poultry/
University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 7, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/university-delaware-study-identifies-optimal-215400486.html
University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250506414477/en/university-of-delaware-study-identifies-optimal-formulation-of-zivo%e2%80%99s-active-ingredients-for-further-testing-to-mitigate-avian-influenza-in-poultry/
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
February 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250206639313/en/zivo-bioscience-plans-new-study-with-university-of-delaware-to-combat-avian-influenza-in-poultry/
Zivo Bioscience issues new shares, raises $1.5 million
January 28, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/zivo-bioscience-issues-new-shares-raises-1-5-million/ar-AA1xZjTM
Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed
January 1, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/tuesdays-insider-activity-top-buys-and-sells-in-us-stocks-revealed-93CH-3793355
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
December 20, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20241220941955/en/ZIVO-Bioscience-Reports-Preliminary-Efficacy-of-its-Proprietary-Active-Ingredients-in-the-Battle-Against-Avian-Influenza/
Regencell Bioscience Holdings Ltd RGC
February 1, 2024  |  morningstar.comM
ZIVO Bioscience Announces Uplisting to OTCQB Market
January 29, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/zivo-bioscience-announces-uplisting-otcqb-130000877.html?.tsrc=rss
Ideaya Biosciences
January 18, 2024  |  forbes.comhttps://www.forbes.com/companies/ideaya-biosciences/
Dare Bioscience Inc DARE
January 14, 2024  |  morningstar.comM
Zivo Bioscience Inc (ZIVO) USD0.001
November 11, 2023  |  hl.co.ukhttps://www.hl.co.uk/shares/shares-search-results/z/zivo-bioscience-inc-usd1.001/costs
Zivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72
November 1, 2023  |  msn.comhttps://www.msn.com/en-us/money/markets/zivo-bioscience-zivo-price-target-increased-by-50000-to-3672/ar-AA1jflXo
Zivo Bioscience Inc ZIVO
November 1, 2023  |  morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Lipocine stock logo

Lipocine NASDAQ:LPCN

$1.72 -0.21 (-10.88%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$1.74 +0.03 (+1.45%)
As of 10/9/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

NuCana stock logo

NuCana NASDAQ:NCNA

$1.10 -0.03 (-2.65%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$1.12 +0.02 (+2.00%)
As of 10/9/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

ZIVO Bioscience stock logo

ZIVO Bioscience NASDAQ:ZIVO

$5.30 +1.06 (+25.00%)
As of 10/9/2026 03:53 PM Eastern

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas